Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBITDA (2021 - 2025)

Krystal Biotech's EBITDA history spans 5 years, with the latest figure at $51.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 17.5% year-over-year to $51.4 million; the TTM value through Dec 2025 reached $206.2 million, up 133.39%, while the annual FY2025 figure was $206.2 million, 133.39% up from the prior year.
  • EBITDA for Q4 2025 was $51.4 million at Krystal Biotech, down from $79.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $80.6 million in Q3 2023 and bottomed at -$51.0 million in Q1 2022.
  • The 5-year median for EBITDA is -$7.8 million (2021), against an average of $4.8 million.
  • The largest annual shift saw EBITDA tumbled 222.47% in 2022 before it skyrocketed 726360.0% in 2025.
  • A 5-year view of EBITDA shows it stood at -$22.0 million in 2021, then plummeted by 42.59% to -$31.3 million in 2022, then soared by 131.02% to $9.7 million in 2023, then surged by 350.75% to $43.8 million in 2024, then increased by 17.5% to $51.4 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBITDA are $51.4 million (Q4 2025), $79.3 million (Q3 2025), and $39.1 million (Q2 2025).